SCLX (Scilex Holding Co) GF Score : 13/100 (As of Mar. 24, 2025)

View and export this data going back to 2022. Start your Free Trial

What is Scilex Holding Co GF Score?

Scilex Holding Co has the GF Score of 13, which implies that the company might have Worst future performance potential, or not enough data.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 1/10
2. Profitability Rank : 2/10
3. Growth Rank : 0/10
4. GF Value Rank : 0/10
5. Momentum Rank : 0/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes Scilex Holding Co might have Worst future performance potential, or not enough data.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Competitive Comparison of Scilex Holding Co's GF Score

For the Drug Manufacturers - General subindustry, Scilex Holding Co's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Scilex Holding Co's GF Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Scilex Holding Co's GF Score distribution charts can be found below:

* The bar in red indicates where Scilex Holding Co's GF Score falls into.

Scilex Holding Co (NAS:SCLX) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score	Performance Potential and All-in-One Screener Examples ⁽¹⁾
91 - 100	Highest outperformance potential
81 - 90	Good outperformance potential
71 - 80	Likely to have average performance
51 - 70	Poor future performance potential
0 - 50	Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

Scilex Holding Co GF Score Related Terms

Thank you for viewing the detailed overview of Scilex Holding Co's GF Score provided by GuruFocus.com. Please click on the following links to see related term pages.

Scilex Holding Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Scilex Holding Co (NAS:SCLX) » Definitions » GF Score

Comparable Companies

Traded in Other Exchanges

N/A

Address

960 San Antonio Road, Palo Alto, CA, USA, 94303

Website

https://www.scilexholding.com

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

Executives

Jaisim Shah	director, officer: See Remarks	C/O PROTINE DESIGN LAB, 37481 MARSTEN DR, NEWARK CA 94560
Henry Ji	director, officer: Executive Chairperson	5370 RUETTE DE MER, SAN DIEGO CA 92130
Jay Chun	director	C/O SCILEX HOLDING COMPANY, 960 SAN ANTONIO ROAD, PALO ALTO CA 94303
Dorman Followwill	director	C/O SORRENTO THERAPEUTICS, INC., 4955 DIRECTOR'S PLACE, SAN DIEGO CA 92121
Yue Alexander Wu	director	C/O SORRENTO THERAPEUTICS, INC., 9380 JUDICIAL DRIVE, SAN DIEGO CA 92121
David Lemus	director	C/O SORRENTO THERAPEUTICS, INC., 4955 DIRECTOR'S PLACE, SAN DIEGO CA 92121
Stephen Hoi Ma	officer: Chief Financial Officer	C/O SCILEX HOLDING COMPANY, 960 SAN ANTONIO ROAD, PALO ALTO CA 94303
Sclx Stock Acquisition Jv Llc	10 percent owner	960 SAN ANTONIO ROAD, PALO ALTO CA 94303
Tommy G Thompson	director	7711 CARONDELET, ST. LOUIS MO 63105
Tien-li Lee	director	C/O SCILEX HOLDING COMPANY, 960 SAN ANTONIO ROAD, PALO ALTO CA 94303
Sorrento Therapeutics, Inc.	10 percent owner	4955 DIRECTORS PLACE, SAN DIEGO CA 92121
Elizabeth Czerepak	officer: See Remarks	201 ROUTE 17 NORTH, RUTHERFORD NJ 07070
Laura Hamill	director	333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Steve Myint	director	C/O VICKERS VANTAGE CORP. I, 1 HARBOURFRONT AVENUE, #16-06, SINGAPORE U0 098632
Chris Ho	director, 10 percent owner, officer: Chief Financial Officer	C/O VICKERS VANTAGE CORP. I, 1 HARBOURFRONT AVENUE, #16-06, SINGAPORE U0 098632